Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants

The Committee on Infectious Diseases of the Korean Pediatric Society

doi:10.3345/CEP.2021.00507

Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants

The Committee on Infectious Diseases of the Korean Pediatric Society

Department of Medicine

Gachon University
Pusan National University
Sungkyunkwan University
Korea University
Eulji University
CHA University School of Medicine
University of Ulsan
Seoul National University
The Catholic University of Korea
Chungnam National University
Yonsei University

Research output: Contribution to journal › Journal article › peer-review

6 Scopus citations

Abstract

In April 2020, the Ministry of Food and Drug Safety licensed a hexavalent combined diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib) conjugated to tetanus protein, and hepatitis B (HepB) (recombinant DNA) vaccine, DTaP-IPV-Hib-HepB (Hexaxim, Sanofi Pasteur), for use as a 3-dose primary series in infants aged 2, 4, and 6 months. The DTaP-IPV-Hib-HepB vaccine is highly immunogenic and safe and provides a long-term immune response based on studies performed in a variety of settings in many countries, including Korea. This report summarizes the Committee on Infectious Diseases of the Korean Pediatric Society guidelines for the use of this newly introduced hexavalent combination vaccine.

Original language	English
Pages (from-to)	602-607
Number of pages	6
Journal	Clinical and Experimental Pediatrics
Volume	64
Issue number	12
DOIs	https://doi.org/10.3345/CEP.2021.00507
State	Published - 2021.12

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Combined
Diphtheria-tetanus-acellular pertussis-inactivate
Infant
Vaccines

Quacquarelli Symonds(QS) Subject Topics

Nursing
Medicine

Access to Document

10.3345/CEP.2021.00507

Cite this

@article{e7f5f735eca849ab821daa10269ffd6a,

title = "Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants",

abstract = "In April 2020, the Ministry of Food and Drug Safety licensed a hexavalent combined diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib) conjugated to tetanus protein, and hepatitis B (HepB) (recombinant DNA) vaccine, DTaP-IPV-Hib-HepB (Hexaxim, Sanofi Pasteur), for use as a 3-dose primary series in infants aged 2, 4, and 6 months. The DTaP-IPV-Hib-HepB vaccine is highly immunogenic and safe and provides a long-term immune response based on studies performed in a variety of settings in many countries, including Korea. This report summarizes the Committee on Infectious Diseases of the Korean Pediatric Society guidelines for the use of this newly introduced hexavalent combination vaccine.",

keywords = "Combined, Diphtheria-tetanus-acellular pertussis-inactivate, Infant, Vaccines",

author = "\{The Committee on Infectious Diseases of the Korean Pediatric Society\} and Cho, \{Hye Kyung\} and Park, \{Su Eun\} and Kim, \{Yae Jean\} and Jo, \{Dae Sun\} and Kim, \{Yun Kyung\} and Eun, \{Byung Wook\} and Lee, \{Taek Jin\} and Jina Lee and Hyunju Lee and Kim, \{Ki Hwan\} and Cho, \{Eun Young\} and Ahn, \{Jong Gyun\} and Choi, \{Eun Hwa\}",

note = "Publisher Copyright: {\textcopyright} 2021 by The Korean Pediatric Society.",

year = "2021",

month = dec,

doi = "10.3345/CEP.2021.00507",

language = "English",

volume = "64",

pages = "602--607",

journal = "Clinical and Experimental Pediatrics",

issn = "2713-4148",

number = "12",

}

Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants. / The Committee on Infectious Diseases of the Korean Pediatric Society.
In: Clinical and Experimental Pediatrics, Vol. 64, No. 12, 12.2021, p. 602-607.

Research output: Contribution to journal › Journal article › peer-review

TY - JOUR

T1 - Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants

AU - The Committee on Infectious Diseases of the Korean Pediatric Society

AU - Cho, Hye Kyung

AU - Park, Su Eun

AU - Kim, Yae Jean

AU - Jo, Dae Sun

AU - Kim, Yun Kyung

AU - Eun, Byung Wook

AU - Lee, Taek Jin

AU - Lee, Jina

AU - Lee, Hyunju

AU - Kim, Ki Hwan

AU - Cho, Eun Young

AU - Ahn, Jong Gyun

AU - Choi, Eun Hwa

PY - 2021/12

Y1 - 2021/12

N2 - In April 2020, the Ministry of Food and Drug Safety licensed a hexavalent combined diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib) conjugated to tetanus protein, and hepatitis B (HepB) (recombinant DNA) vaccine, DTaP-IPV-Hib-HepB (Hexaxim, Sanofi Pasteur), for use as a 3-dose primary series in infants aged 2, 4, and 6 months. The DTaP-IPV-Hib-HepB vaccine is highly immunogenic and safe and provides a long-term immune response based on studies performed in a variety of settings in many countries, including Korea. This report summarizes the Committee on Infectious Diseases of the Korean Pediatric Society guidelines for the use of this newly introduced hexavalent combination vaccine.

AB - In April 2020, the Ministry of Food and Drug Safety licensed a hexavalent combined diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib) conjugated to tetanus protein, and hepatitis B (HepB) (recombinant DNA) vaccine, DTaP-IPV-Hib-HepB (Hexaxim, Sanofi Pasteur), for use as a 3-dose primary series in infants aged 2, 4, and 6 months. The DTaP-IPV-Hib-HepB vaccine is highly immunogenic and safe and provides a long-term immune response based on studies performed in a variety of settings in many countries, including Korea. This report summarizes the Committee on Infectious Diseases of the Korean Pediatric Society guidelines for the use of this newly introduced hexavalent combination vaccine.

KW - Combined

KW - Diphtheria-tetanus-acellular pertussis-inactivate

KW - Infant

KW - Vaccines

UR - https://www.scopus.com/pages/publications/85124351583

U2 - 10.3345/CEP.2021.00507

DO - 10.3345/CEP.2021.00507

M3 - Journal article

AN - SCOPUS:85124351583

SN - 2713-4148

VL - 64

SP - 602

EP - 607

JO - Clinical and Experimental Pediatrics

JF - Clinical and Experimental Pediatrics

IS - 12

ER -

Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants

Abstract

UN SDGs

Keywords

Quacquarelli Symonds(QS) Subject Topics

Access to Document

Other files and links

Fingerprint

Cite this